These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 9028327

  • 1. Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia.
    Selleri C, Sato T, Del Vecchio L, Luciano L, Barrett AJ, Rotoli B, Young NS, Maciejewski JP.
    Blood; 1997 Feb 01; 89(3):957-64. PubMed ID: 9028327
    [Abstract] [Full Text] [Related]

  • 2. Fas-mediated modulation of Bcr/Abl in chronic myelogenous leukemia results in differential effects on apoptosis.
    Selleri C, Maciejewski JP, Pane F, Luciano L, Raiola AM, Mostarda I, Salvatore F, Rotoli B.
    Blood; 1998 Aug 01; 92(3):981-9. PubMed ID: 9680367
    [Abstract] [Full Text] [Related]

  • 3. Effects of the tyrosine kinase inhibitor AG957 and an Anti-Fas receptor antibody on CD34(+) chronic myelogenous leukemia progenitor cells.
    Carlo-Stella C, Regazzi E, Sammarelli G, Colla S, Garau D, Gazit A, Savoldo B, Cilloni D, Tabilio A, Levitzki A, Rizzoli V.
    Blood; 1999 Jun 01; 93(11):3973-82. PubMed ID: 10339507
    [Abstract] [Full Text] [Related]

  • 4. The role of FAS-mediated apoptosis in chronic myelogenous leukemia.
    Selleri C, Maciejewski JP.
    Leuk Lymphoma; 2000 Apr 01; 37(3-4):283-97. PubMed ID: 10752980
    [Abstract] [Full Text] [Related]

  • 5. Interferon-alpha and bcr-abl antisense oligodeoxynucleotides in combination enhance the antileukemic effect and the adherence of CML progenitors to preformed stroma.
    Bellucci R, Sala R, De Propris MS, Cordone I, de Fabritiis P.
    Leuk Lymphoma; 1999 Nov 01; 35(5-6):471-81. PubMed ID: 10609784
    [Abstract] [Full Text] [Related]

  • 6. Interferon-alpha restores normal beta 1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia.
    Bhatia R, McCarthy JB, Verfaillie CM.
    Blood; 1996 May 01; 87(9):3883-91. PubMed ID: 8611716
    [Abstract] [Full Text] [Related]

  • 7. Transforming growth factor beta3 inhibits chronic myelogenous leukemia hematopoiesis by inducing Fas-independent apoptosis.
    Fogli M, Carlo-Stella C, Curti A, Ratta M, Tazzari PL, Ragazzi E, Colla S, Santucci AM, Tura S, Lemoli RM.
    Exp Hematol; 2000 Jul 01; 28(7):775-83. PubMed ID: 10907639
    [Abstract] [Full Text] [Related]

  • 8. Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on 'in vitro' growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors.
    Visani G, Russo D, Ottaviani E, Tosi P, Damiani D, Michelutti A, Manfroi S, Baccarani M, Tura S.
    Leukemia; 1997 May 01; 11(5):624-8. PubMed ID: 9180282
    [Abstract] [Full Text] [Related]

  • 9. Eilatin: a novel marine alkaloid inhibits in vitro proliferation of progenitor cells in chronic myeloid leukemia patients.
    Einat M, Lishner M, Amiel A, Nagler A, Yarkorli S, Rudi A, Kashman Y, Markel D, Fabian I.
    Exp Hematol; 1995 Dec 01; 23(14):1439-44. PubMed ID: 8542929
    [Abstract] [Full Text] [Related]

  • 10. Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro.
    Maciejewski J, Selleri C, Anderson S, Young NS.
    Blood; 1995 Jun 01; 85(11):3183-90. PubMed ID: 7538820
    [Abstract] [Full Text] [Related]

  • 11. L-selectin expression is low on CD34+ cells from patients with chronic myeloid leukemia and interferon-a up-regulates this expression.
    Martín-Henao GA, Quiroga R, Sureda A, González JR, Moreno V, García J.
    Haematologica; 2000 Feb 01; 85(2):139-46. PubMed ID: 10681720
    [Abstract] [Full Text] [Related]

  • 12. Potential mechanisms of action of interferon-alpha in CML.
    Dowding C, Gordon M, Guo AP, Maison D, Osterholz J, Siczkowski M, Goldman J.
    Leuk Lymphoma; 1993 Feb 01; 11 Suppl 1():185-91. PubMed ID: 7504544
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Differential effect of type I interferons on hematopoietic progenitor cells: failure of interferons to inhibit IL-3-stimulated normal and CML myeloid progenitors.
    Després D, Goldschmitt J, Aulitzky WE, Huber C, Peschel C.
    Exp Hematol; 1995 Dec 01; 23(14):1431-8. PubMed ID: 8542928
    [Abstract] [Full Text] [Related]

  • 18. The anti-tumor activities of interferon (IFN)-alpha in chronic myelogenous leukaemia (CML)-derived cell lines depends on the IFN-alpha subtypes.
    Yanai Y, Sanou O, Yamamoto K, Yamauchi H, Ikegami H, Kurimoto M.
    Cancer Lett; 2002 Nov 28; 185(2):173-9. PubMed ID: 12169391
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Immunological effects of interferon-alpha on chronic myelogenous leukemia.
    de Castro FA, Palma PV, Morais FR, Simões BP, Carvalho PV, Ismael SJ, Lima CP, Voltarelli JC.
    Leuk Lymphoma; 2003 Dec 28; 44(12):2061-7. PubMed ID: 14959848
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.